Singapore, December 21, 2021 – In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on December 17th, 2021.
According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay is capable of correctly detecting the new Omicron strain, including B.1.1.529 BA.1 and BA.2.
Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly
Another four Variants of Concern (VOC):
． Alpha variant: known as B.1.1.7
． Beta variant: known as B.1.351
． Gamma variant: known as P.1
． Delta variant: known as B.1.617.2
Two Variants of Interest (VOI):
． Lambda variant: known as C.37
． Mu variant: known as B.1.621
The other six variants:
． Eta variant: known as B.1.525
． Iota variant: known as B.1.526
． Kappa variant: known as B.1.617.1
． Zeta variant: known as P.2
． Epsilon variant: known as B.1.427/B.1.429
． Indian variant: known as B.1.617.3
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.